This article is more than 5 years old. Information may no longer be current.

Tarsus raises $60 million in Series B financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing that will be used to initiate a phase 2b/3 trial of topical ophthalmic TP-03 for the treatment of Demodex blepharitis.

Funds will also be used to “fuel phase 1 and 2 development of other clinical programs,” according to a company press release.

“We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine,” Michael Ackermann, PhD, Tarsus chairman, said in the release.

Included in the financing round, led by Vivo Capital, were Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group.